Novo Nordisk's experimental obesity drug CagriSema produced 25% weight loss on average in adult women in post-trial analyses, with reductions in abdominal fat across menopausal stages.
01Summary
- 01CagriSema, a combination of semaglutide and cagrilintide, caused 25% weight loss at 68 weeks in an analysis of 2,300 women versus 3% with placebo.
- 02Weight loss reached 26.7%, 24.8%, and 23.1% in premenopausal, perimenopausal and postmenopausal women, respectively, in a separate analysis of 1,900 women.
- 03The drug is expected to launch early next year; analysts forecast $11.84 billion in obesity sales by 2028.
- 04Initial phase 3 trial results showed 22.7% average weight loss in a broader population of 3,400 adults, 67% of whom were women.
- 05More than 86 million women in the US are aged 40 and older, the years when perimenopause, menopause, and postmenopause occur.
02Why it matters
This matters because CagriSema targets weight gain during menopause—a common struggle for millions of women—and could offer a more effective alternative to existing GLP-1 drugs like Wegovy.
Pulse AIAsk about this story
Answers are generated by AI from the story summary; they are not investment, health or legal advice.
